This document is an excerpt from the EUR-Lex website
Document 92003E001494
WRITTEN QUESTION E-1494/03 by Elly Plooij-van Gorsel (ELDR) to the Commission. Expressions of interest in the Sixth Framework Programme of Research for embryo research and stem cell research.
WRITTEN QUESTION E-1494/03 by Elly Plooij-van Gorsel (ELDR) to the Commission. Expressions of interest in the Sixth Framework Programme of Research for embryo research and stem cell research.
WRITTEN QUESTION E-1494/03 by Elly Plooij-van Gorsel (ELDR) to the Commission. Expressions of interest in the Sixth Framework Programme of Research for embryo research and stem cell research.
OJ C 33E, 6.2.2004, p. 127–127
(ES, DA, DE, EL, EN, FR, IT, NL, PT, FI, SV)
|
6.2.2004 |
EN |
Official Journal of the European Union |
CE 33/127 |
(2004/C 33 E/126)
WRITTEN QUESTION E-1494/03
by Elly Plooij-van Gorsel (ELDR) to the Commission
(2 May 2003)
Subject: Expressions of interest in the Sixth Framework Programme of Research for embryo research and stem cell research
On 20 March 2002 the Commission published an invitation to submit expressions of interest in the Sixth Framework Programme of Research (FP6). Until 7 June 2002, scientific institutes and businesses could submit plans to the Commission for assessment as to their suitability for support from the Framework Programme. On 4 October 2002 the Commission published the results.
From the published results it emerges that in 1997 expressions of interest were submitted for the thematic priority ‘Life sciences, genomics and biotechnology’. This priority includes financial support for stem cell research.
The regulation of human embryonic stem cell research is subject to subsidiarity in Europe, and different practices exist in the Member States in this regard. In some Member States, for example, it is permitted to produce human embryos for research purposes, whereas in other Member States this is explicitly prohibited.
Under the compromise reached between the Council and the European Parliament in September 2002 concerning the five specific programmes within the FP, it was agreed that until the end of 2003 the Commission should not finance any research programmes which included embryonic stem cell research.
|
1. |
How many expressions of interest have been submitted to the Commission under the thematic priority ‘Life sciences, genomics and biotechnology’ which involve embryonic stem cell research? |
|
2. |
In which Member States are the scientific institutes and/or businesses based which submitted these expressions of interest? |
Answer given by Mr Busquin on behalf of the Commission
(13 June 2003)
The Priority 1 Life ‘Sciences, Genomics and Biotechnology for Health’ received 2000 Expressions of Interest (EoI). About 80 expressions of interest involving research on stem cell (animal or human stem cells) were submitted.
The various sources of stem cells were explored (embryonic, foetal, umbilical cord blood, adult). The specific sources of stem cells were not indicated in all EoI’s nor was the country in which the specific research was going to be carried out. The Commission is therefore not in a position to provide more detailed information regarding the number of EoI’s, which involve the use of human embryonic stem cells and the countries where this research is planned to take place.
A first call for proposals for Priority 1 was published on 17 December 2002 and closed on 25 March 2003. At this stage of the analysis of the response to the call for proposals the Thematic Priority 1 has received 26 proposals addressing research on stem cells and three proposals foresee to use banked or isolated human embryonic stem cell in culture. This research involves laboratories in Belgium, Finland, Sweden, the United Kingdom, the Czech Republic and Israel.